Latest Updates of Companies in the Autoinjectors Market
| Company | Headquarters | Latest Update |
| Eli Lilly and Company | United States | In February 2026, Eli Lilly and Company announced the U.S. Food and Drug Administration (FDA) approved a label expansion for Zepbound to include the four-dose single-patient use KwikPen that delivers a full month of treatment in one tool. |
| Amgen | United States | In October 2025, Amgen announced the launch of AmgenNow, a novel direct-to-patient program starting with Repatha. |
| Ypsomed | United States | In October 2026, Ypsomed launches YpsoLoop, the first autoinjector platform designed for circularity. The two new 1 ml and 2 ml platform versions enable material recovery through a design enabling automated disassembly. |
| SHL Medical | United States | In March 2025, SHL Medical AG, the worldwide leader in advanced drug delivery services, announced a strategic collaboration with Thermo Fisher Scientific Inc., the world leader in serving science. |
| AbbVie | United States | In April 2026, AbbVie submitted a supplemental application to the FDA seeking approval for subcutaneous (SC) risankizumab-rzaa as an induction therapy for adults with moderately to severely active Crohn disease. |
Recent Developments in the Autoinjectors Market
- In April 2026, AstraZeneca’s SAPHNELO was approved in the US for self-administration as a once-weekly autoinjector, the SAPHNELO Pen, for the treatment of adult patients with systemic lupus erythematosus on top of standard therapy.
- In November 2025, Sempresto, Inc., a medical device organization pioneering smartphone-integrated rescue drug delivery, announced the acquisition of all patents and related physical and digital assets from inventor Steven A. Friedman.
- In October 2025, Amneal Pharmaceuticals, Inc. announced the U.S. commercial launch of Brekiya injection, the first and only ready-to-use dihydroergotamine (DHE) autoinjector approved for the acute treatment of migraine with or without aura and the acute treatment of cluster headaches in adults.
Supply Chain Analysis
R&D:
- Research and development (R&D) in autoinjector therapy involves concept generation & feasibility research, design and engineering development, human factors engineering (HFE) and usability testing, prototypes and technical verification testing, manufacturing process development, and regulatory and clinical validation
- Key Players: SHL Medical and Ypsomed Holding AG
Manufacturing Processes:
- Manufacturing processes in rare disease-focused cell & gene therapy CDMOs are increasing, including precision injection molding, metal component production, assembly processes, in-process quality control (IPQC) and metrology, and traceability and finishing.
- Key Players: Becton, Dickinson and Company and West Pharmaceutical Services, Inc.
Patient Services:
- Patient services related to autoinjectors are designed to simplify self-administration, enhance treatment adherence, and improve safety, specifically for chronic conditions.
- Key Players: Gerresheimer AG and Owen Mumford
Market Growth
The global autoinjectors market size was estimated at USD 3.95 billion in 2025 and is predicted to increase from USD 4.42 billion in 2026 to approximately USD 12.05 billion by 2035, expanding at a CAGR of 11.8% from 2026 to 2035. The autoinjector market is growing because these tools increase patient compliance and adherence, as the drugs can be self-administered.
Keypoints
- Company Overview
- Locations Subsidiaries/Geographic reach
- Key Executives
- Company Financials
- Patents registered
- SWOT Analysis
- Applications Catered
- Strategic collaborations
- Recent Developments
- Competitive Benchmarking